News
Lack of integration with Brown and the affiliated teaching hospitals restricts economic development in Rhode Island, report finds.
This continues to outpace previous years' enrollment, including a 21% increase in plan selections through December 15, 2021.
Currently, Aduhelm, made by Biogen, is the only monoclonal antibody approved by the FDA for the treatment of Alzheimer's disease.
Hoag will become an independent entity, ending a 10-year affiliation that first showed strains during a 2020 lawsuit.
The goal is to incentivize insurers to cover these costs up-front and ensure patients don't need an order from their providers.
Premiums covered the $56,000 yearly cost of the Alzheimer's drug Aduhelm, but that price has been slashed by 50%.
There are no test-out options and no exemptions, apart from medical exemptions, a move geared to protecting the health of a stretched-thin workforce.
The current results stand in contrast to recent studies that found most mergers do not improve quality or safety.
The deal advances R1's integrated technology strategy through revenue intelligence and automation.
CEO says aggressive pricing from marketplace rivals has played a role in the new projections, shifting the focus to business-wide profitability.